Surrozen, Inc. · NASDAQ:SRZN
Surrozen — Investor Presentation (March 2026)
21 slides from Surrozen's investor presentation, March 2026
Slide 1: Restoring Vision Through the Science of Renewal
Restoring Vision Through the Science of Renewal © 2026 Surrozen, Inc. March 2026
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and simila
Slide 3: Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease
Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease Clear Rationale for Combining Complementary MOAs • Commercial: Market leader (Vabysmo) combines two targets • Clinical: Compelling clinical benefit across studies and retinopathies for combining MOAs Pursuing the Opti
Slide 4: Retinal Vascular Diseases are Large and Growing Markets with Significant Unmet Need
Retinal Vascular Diseases (DME, wet AMD) are Large and Growing Markets with Significant Unmet Need Retinal Vascular Diseases Global Anti-VEGF Agents US Prevalence1 2.3M Ophthalmic Drug Market Global >40M2,3 Prevalence $25 Anti-VEGF $13B in 2025 -> >$20B in 2030 $20 Market4-6 CAGR: ~10% Annual Sales
Slide 5: Vabysmo (VEGF + Ang2): Blueprint for VEGF Combinations
Vabysmo (VEGF + Ang2): Blueprint for VEGF Combinations Multiple targets drive additional clinical benefit Incremental drying leads to rapid adoption Vabysmo Clinical Outcomes in DME Global Vabysmo Revenue $6.0 Vabysmo Launch $5.0 Annual Sales ($B) $4.0 $3.0 $2.0 $1.0 $0.0 © 2026 Surrozen, Inc. 2022
Slide 6: Evidence that Adding to VEGF Inhibition Confers Additive Clinical Benefit
Evidence that Adding to VEGF Inhibition Confers Additive Clinical Benefit Roche demonstrated IL-6 in combination with VEGF inhibition superior to VEGF alone Ph II (BARDENAS): Anti-IL-6 (vamikibart) + anti-VEGF (ranibizumab) showed superior efficacy in DME Consistent BCVA gains for combination throug
Slide 7: Wnt Signaling: A Key Regulator of Vascular Biology
Wnt Signaling A Key Regulator of Vascular Biology
Slide 8: Wnt is A Key Regulator of Retinal Vascular Function
Wnt is A Key Regulator of Retinal Vascular Function A complementary mechanism to VEGF inhibition Oxygen Induced Retinopathy Model • Biology: Wnt signaling is essential for maintaining retinal vascular integrity and barrier function Avascular area/Total area (%) 30 20 Vehicle Tuft area/Total (%) Afli
Slide 9: Wnt Biology is Driving Strategic Investment
Wnt Biology is Driving Strategic Investment SURROZEN’S SZN-413 | 2022 2024 • Potential best-in-class FZD4 /LRP bi-specific antibody for retinal diseases like neovascular AMD Merck acquired EyeBio in and DME 2024 for $1.3B for Restoret (EYE103, MK-3000) • Licensed to Boehringer Ingelheim in October 2
Slide 10: Surrozen Advantage: Defining the Next Era of Retinal Repair
Surrozen Advantage: Defining the Next Era of Retinal Repair Architects of Drugging the Next Generation Multifunctional Pathway: Biologics: Built by the world’s leading experts who First-in-class multifunctional biologics which discovered the Wnt pathway, its role in tissue combine Wnt activation wit
Slide 11: Our Development Pipeline
Our Development Pipeline ) Surrozen
Slide 12: SZN-413: First FZD4/LRP5 Antibody Targeting Wnt Activation
SZN-413: First FZD4/LRP5 Antibody Targeting Wnt Activation Wnt Pathway: SZN-413 Distinct Mechanism of Vascular Repair Clustering FZD4 and LRP5 receptors on retinal vascular endothelial cells via a multi-valent, bi-specific antibody Novel mechanism for treatment of retinal activates the Wnt signal tr
Slide 13: Second Generation Multi-Functional Wnt Targeted Antibodies
Second Generation Multi-Functional Wnt Targeted Antibodies Complementary mechanisms enable potential best-in-disease antibodies SZN-8141 – WNT Activation + VEGF Inhibition Wnt activation via FZD4/LRP5 • Potential for best-in-class Wnt activation • Wnt activation upregulates tight junction proteins a
Slide 14: SZN-8141 Restores Retinal Vessel Architecture
SZN-8141 Restores Retinal Vessel Architecture Oxygen Induced Retinopathy Model Avascular area Retinal flat mount Control SZN-8141 10 Avascular area (% of total area) 8 80% reduction in avascular area © 2026 Surrozen, Inc. 6 Novel mechanism for treatment of retinal vascular diseases that can 4 direct
Slide 15: SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A
SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A In vitro assays demonstrate similar potency, affinity and binding to aflibercept KDR/NFAT-RE HEK293 Binding Affinity Cell Potency Assay to VEGF (Kd) 5000000 4000000 SZN-8141 Aflibercept <1pM <1pM 3000000 RLU 2000000 Aflibercept 1000000 SZN-8
Slide 16: SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism
SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism OIR Model (Delayed) Reduction of avascular area Avascular area (% of total area) 20 15 **** 10 **** 5 ****,# 0 Negative Anti-VEGF FZD4 Anti-VEGF + SZN-8141 Control Agonist FZD4 Agonist Reduction of neovascularization Neovascular area (% of t
Slide 17: SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit
SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit in UME and Other Retinal Vascular Diseases SZN-8143 – WNT + VEGF + IL-6 Wnt activation via FZD4/LRP5 Fv:VHH Additional Fc IL-6 inhibition via anti-IL-6 IgG engineering to reduce liabilities • Reduces vascular permeability and VEGF pr
Slide 18: Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology
Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology Pipeline Wnt agonists show promising preclinical activity across multiple disease models Fuchs’ Endothelial Dystrophy Program • Loss of corneal endothelial cells causes corneal swelling, haziness and vision loss, accompanied b
Slide 19: Ophthalmology Franchise: Multiple Novel High Value Candidates
Ophthalmology Franchise: Multiple Novel High Value Candidates PROGRAM INDICATION RESEARCH PRE-CLINICAL PHASE 1 SZN-413* Retinopathies FZD4 SZN-8141 wet AMD, DME FZD4, VEGF SZN-8143 wet AMD, DME, UME FZD4, VEGF, IL-6 Research Ocular disease © 2026 Surrozen, Inc. Glossary: FZD - frizzled; VEGF - Vascu
Slide 20: Thank You
Thank You www.surrozen.com © 2026 Surrozen, Inc. March 2026
Slide 21: Glossary
Glossary AMD Age-related macular degeneration Lrp Lipoprotein receptor-related protein DME Diabetic macular edema POC Proof-of-concept ECM Extracellular matrix OIR Oxygen induced retinopathy FEVR Familial exudative vitreoretinopathy RPE Retinal pigment epithelium FZD Frizzled UME Uveitic macular ede